Research Article
Association of AGTR1 A1166C and CYP2C9∗3 Gene Polymorphisms with the Antihypertensive Effect of Valsartan
Table 4
Combined effect of AGTR1 A1166C and CYP2C9∗3 polymorphisms on antihypertensive efficacy of valsartan.
| | | Unadjusted | Adjusted | | OR (95% CI) | | OR (95% CI) | |
| | Genotype (AGTR1 + CYP2C9) | | | | | | AA + ∗1/∗1 | 1a | — | 1a | — | | AA + ∗1/∗3 | 0.587 (0.237–1.454) | 0.250 | 0.626 (0.239–1.641) | 0.341 | | (AC + CC) + ∗1/∗1 | 2.953 (1.267–6.880) | 0.012 | 3.028 (1.225–7.486) | 0.016 | | (AC + CC) + ∗1/∗1 | 2.054 (0.184–22.976) | 0.559 | 0.606 (0.034–10.859) | 0.734 | | Age | — | — | 1.035 (1.004–1.067) | 0.028 | | Gender | — | — | 0.763 (0.372–1.566) | 0.460 | | BMI | — | — | 1.001 (0.925–1.085) | 0.971 | | Grade of hypertension | | | | | | Grade 1 | — | — | 1a | — | | Grade 2 | — | — | 1.050 (0.423–2.607) | 0.917 | | Grade 3 | — | — | 0.516 (0.227–1.169) | 0.113 | | History of drinking | — | — | 0.629 (0.325–1.220) | 0.170 | | History of smoking | — | — | 0.770 (0.398–1.488) | 0.436 |
|
|
aReference category (odds ratio, 1). BMI: body mass index; CI: confidence interval; OR: odds ratio.
|
